[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma Plc LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 81.50 78.00 85.00 81.50 81.50 81.50 22,446 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.7 -9.2 -5.4 - 224

Redx Pharma Share Discussion Threads

Showing 651 to 673 of 675 messages
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
DateSubjectAuthorDiscuss
11/1/2022
11:00
Looking ready for a breakout on the up side.
knitcraft
23/12/2021
07:39
Another great Milestone payment RNS. Well done REDX and Merry Christmas all holders.
wapper
09/12/2021
08:29
UK, 9 December 2021 - Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that a milestone payment from Jazz Pharmaceuticals (NASDAQ: JAZZ) has been triggered as a result of entering the second year of the oncology research collaboration with the Company. The milestone payment of $10 million arises in accordance with the terms of the research collaboration agreement announced on 9 September 2020. Under the agreement to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway, Redx is responsible for research and preclinical development activities up to Investigational New Drug (IND) submission. In addition to the $20 million in payments that have now been realised, Redx may receive up to a further $200 million from Jazz in development, regulatory and commercial milestone payments for each programme. The next milestone is payable upon successful IND submission and all subsequent milestones are contingent on successful completion of the relevant stages of development. In addition, Redx is eligible for tiered royalties in mid-single digit percentages, based on any future net sales. Lisa Anson, Chief Executive Officer of Redx, commented: "We are extremely pleased to extend our productive oncology research collaboration with Jazz into its second year. This is based on advancing our programmes in this key signalling pathway and reflects Redx's core strength in discovering highly targeted potential drug candidates. We look forward to further progress in partnership with Jazz." Redx continues to execute on its strategy, progressing its lead oncology and fibrosis programmes. These include the oral Porcupine inhibitor, RXC004, targeting Wnt-ligand driven tumours, which has recently entered a Phase 2 trial in genetically selected patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) and the oral selective ROCK2 inhibitor, RXC007, being developed for idiopathic pulmonary fibrosis, where first in human studies commenced in June 2021.
wapper
15/9/2021
09:45
Completely different management these days. Seem to be doing a great job. Statement next week is expected to be very positive. Tremendous potential to make a difference to Cancer and Fibrosis treatment. It will all take time to materialise but is well worth the wait as a shareholder.
knitcraft
14/9/2021
20:16
gutted sold at 70p
latifs100
14/9/2021
09:22
Well done Wapper!
chesty1
14/9/2021
09:22
I’m being greedy, average buy price is 53p but I’ll stick with it.
macmoss
14/9/2021
09:21
CHESTY ....Look at the increase since my post on 6th. Over 50% . I rest my case .Good luck to you and all holders here. I love the Company but sometimes we have to make difficult decisions. Buying is easy : selling is always harder as we all know.
wapper
14/9/2021
09:15
Wapper6 Sep '21 - 08:27 - 489 of 497 0 0 0 Great day so far. Still way undervalued Wapper14 Sep '21 - 09:55 - 496 of 497 0 0 0 I'm out and very happy with a 3 bagger. WOW!!!!
chesty1
14/9/2021
08:58
Added to my KOD holding with some of REDX cash
wapper
14/9/2021
08:55
I'm out and very happy with a 3 bagger. Just feel it's possibly getting ahead of itself now but it's only a gut feel so no advice intended. Sorry to see it leave my portfolio and will keep on watch list
wapper
14/9/2021
08:47
i have copied this from another bb! 05/09/21 The Sunday Times article mentions Redx's BTK inhibitor that was sold to Loxo Oncology - the first of Redx's molecules to be monetised. Loxo was subsequently bought by Eli Lilly and Redx's BTK inhibitor now goes under the name of Pirtobrutinib. Lilly have been pressing ahead with clinical trials and Pirtobrutinib is now regarded as one of the most promising candidates in their pipeline. Only a few days ago, really impressive phase I/II results in lymphoma were presented at the 2021 Pan Pacific Lymphoma Conference with an overall MCL response rate of 52% and a complete response rate of 25%. These rates were achieved in patients who had been heavily pretreated and failed on other therapies, including other BTK inhibitors, CAR-T and stem cell transplants. Even higher responses were seen in other types of lymphoma. Pirtobrutinib is now undergoing phase III studies. The point is that industry will be aware of the quality of the molecules coming out of Redx's labs and the success to date of Pirtobrutinib will not be lost on any who may be watching the progress of RXC004 - phase I clinical trial results are due to be presented at ESMO in a couple of weeks. https://www.onclive.com/view/pirtobrutinib-exhibits-promising-efficacy-in-heavily-pretreated-mcl-and-other-non-hodgkin-lymphomas
demark
10/9/2021
18:08
Any update amrish? I think we would all appreciate your views on the future of Redx and it’s share price
knitcraft
06/9/2021
09:27
That sucks on all top three raise shares
amrishbhim
06/9/2021
08:56
Dnt be impaled in this
kevinroe
06/9/2021
07:50
up 28%, but spread 4p
latifs100
06/9/2021
07:27
Great day so far. Still way undervalued
wapper
05/9/2021
13:33
Thanks Knitcraft. Good article. £1.35 price target
wapper
05/9/2021
11:28
A very good appraisal of Redx in today’s Sunday Times Business Section. Finishes off with a “buy” recommendation. Worth a read..
knitcraft
02/9/2021
06:57
Welcome news this morning along with a reminder of just how big this could be .Happy to hold
wapper
30/3/2021
11:33
Looks like RedX is coming good for investors. Anyone who can be bothered to look more deeply into what has been achieved in the last 12 months will realise what an opportunity presents itself. They are on the cusp of tremendous results to benefit cancer and fibrosis patients. There are only 8% of the shares available in the market. Any positive news from just one of their research projects will transform RedX.They are presenting to a conference in the US in 10 days. Look into the background of the team for any reassurance on what they bring to the company. Funding is in place for two years of funding at the end of which the share price could be many multiples of today's breakout figure of 75.
knitcraft
27/1/2021
07:42
All on track. Still see this as a bagger in waiting. Happy to hold and accumulate on any weakness . Might be an interesting day here. GLAH
wapper
27/1/2021
07:26
Looks like they are expecting a transformational year especially if milestones are hit and they start receiving the payments from Glaxo (up to 360m) and Jazz (up to 400m) which were agreed last year.
supercity
Chat Pages: 27  26  25  24  23  22  21  20  19  18  17  16  Older
ADVFN Advertorial
Your Recent History
LSE
REDX
Redx Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220120 22:13:38